학술논문
Symptomology following mRNA vaccination against SARS-CoV-2
Document Type
article
Author
Ebinger, Joseph E; Lan, Roy; Sun, Nancy; Wu, Min; Joung, Sandy; Botwin, Gregory J; Botting, Patrick; Al-Amili, Daniah; Aronow, Harriet; Beekley, James; Coleman, Bernice; Contreras, Sandra; Cozen, Wendy; Davis, Jennifer; Debbas, Philip; Diaz, Jacqueline; Driver, Matthew; Fert-Bober, Justyna; Gu, Quanquan; Heath, Mallory; Herrera, Ergueen; Hoang, Amy; Hussain, Shehnaz K; Huynh, Carissa; Kim, Linda; Kittleson, Michelle; Liu, Yunxian; Lloyd, John; Luong, Eric; Malladi, Bhavya; Merchant, Akil; Merin, Noah; Mujukian, Angela; Nguyen, Nathalie; Nguyen, Trevor-Trung; Pozdnyakova, Valeriya; Rashid, Mohamad; Raedschelders, Koen; Reckamp, Karen L; Rhoades, Kylie; Sternbach, Sarah; Vallejo, Rocío; White, Shane; Tompkins, Rose; Wong, Melissa; Arditi, Moshe; Figueiredo, Jane C; Van Eyk, Jennifer E; Miles, Peggy B; Chavira, Cynthia; Shane, Rita; Sobhani, Kimia; Melmed, Gil Y; McGovern, Dermot PB; Braun, Jonathan G; Cheng, Susan; Minissian, Margo B
Source
Subject
Language
Abstract
Despite demonstrated efficacy of vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease-2019 (COVID-19), widespread hesitancy to vaccination persists. Improved knowledge regarding frequency, severity, and duration of vaccine-associated symptoms may help reduce hesitancy. In this prospective observational study, we studied 1032 healthcare workers who received both doses of the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine and completed post-vaccine symptom surveys both after dose 1 and after dose 2. We defined appreciable post-vaccine symptoms as those of at least moderate severity and lasting at least 2 days. We found that symptoms were more frequent following the second vaccine dose than the first (74% vs. 60%, P 80% of all symptoms resolving within 2 days. The most common symptom was injection site pain, followed by fatigue and malaise. Overall, 20% of participants experienced appreciable symptoms after dose 1 and 30% after dose 2. In multivariable analyses, female sex was associated with greater odds of appreciable symptoms after both dose 1 (OR, 95% CI 1.73, 1.19-2.51) and dose 2 (1.76, 1.28-2.42). Prior COVID-19 was also associated with appreciable symptoms following dose 1, while younger age and history of hypertension were associated with appreciable symptoms after dose 2. We conclude that most post-vaccine symptoms are reportedly mild and last